nach oben

Die Dermatologie

Erschienen in:

01.03.2021 | Dermatomyositis | Leitthema

Paraneoplastische Autoimmundermatosen

verfasst von: D. Didona, M. Hertl

Erschienen in: Die Dermatologie | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Paraneoplastische Hautmanifestationen bei Malignomen sind polymorph. Kliniker sollten mit paraneoplastischen Dermatosen vertraut gemacht werden, um eine Frühdiagnose des begleitenden Malignoms durchführen zu können. Mangelnde Vertrautheit mit kutanen Hinweisen auf bösartige innere Erkrankungen kann ihre Diagnose und Behandlung verzögern. In dieser Übersicht haben wir mehrere paraneoplastische autoimmune Dermatosen beschrieben, darunter das paraneoplastische autoimmune Multiorgansyndrom (PAMS), das paraneoplastische bullöse Pemphigoid und die paraneoplastische Dermatomyositis.

Amber KT (2018) Paraneoplastic autoimmune multi-organ syndrome is a distinct entity from traditional pemphigus subtypes. Nat Rev Dis Primers 4:18012PubMedCrossRef

Amber KT, Maglie R, Solimani F, Eming R, Hertl M (2018a) Targeted therapies for autoimmune bullous diseases: current status. Drugs 78:1527–1548PubMedCrossRef

Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L (2018b) Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. Clin Rev Allergy Immunol 54:26–51PubMedCrossRef

Amber KT, Valdebran M, Grando SA (2018c) Paraneoplastic autoimmune multiorgan syndrome (PAMS): beyond the single phenotype of paraneoplastic pemphigus. Autoimmun Rev 17:1002–1010PubMedCrossRef

András C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P, Dankó K (2008) Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35:438–444PubMed

Anhalt GJ (2001) Paraneoplastic pemphigus: the role of tumours and drugs. Br J Dermatol 144:1102–1104PubMedCrossRef

Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, Izumi H, Ratrie H, Mutasim D, Ariss-Abdo L (1990) Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 323:1729–1735PubMedCrossRef

Azuma K, Yamada H, Ohkubo M, Yamasaki Y, Yamasaki M, Mizushima M, Ozaki S (2011) Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 21:178–183PubMedCrossRef

Bağcı IS, Horváth ON, Ruzicka T, Sárdy M (2017) Bullous pemphigoid. Autoimmun Rev 16:445–455PubMedCrossRef

10.

Balin SJ, Wetter DA, Andersen LK, Davis MDP (2012) Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996–2009. Arch Dermatol 148:455–462PubMedCrossRef

11.

Bazzini C, Begré N, Favre B, Hashimoto T, Hertl M, Schlapbach C, Borradori L (2020) Detection of autoantibodies against alpha-2-macroglobulin-like 1 in paraneoplastic pemphigus sera utilizing novel green fluorescent protein-based immunoassays. J Dermatol Sci 98:173–178PubMedCrossRef

12.

Bech R, Baumgartner-Nielsen J, Peterslund NA, Steiniche T, Deleuran M, d’Amore F (2013) Alemtuzumab is effective against severe chronic lymphocytic leukaemia-associated paraneoplastic pemphigus. Br J Dermatol 169:469–472PubMedCrossRef

13.

Bernard P, Antonicelli F (2017) Bullous pemphigoid: a review of its diagnosis, associations and treatment. Am J Clin Dermatol 18:513–528PubMedCrossRef

14.

Bohan A, Peter JB (1975a) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347PubMedCrossRef

15.

Bohan A, Peter JB (1975b) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407PubMedCrossRef

16.

Buchbinder R, Forbes A, Hall S, Dennett X, Giles G (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 134:1087–1095PubMedCrossRef

17.

Buchbinder R, Hill CL (2002) Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep 4:415–426PubMedCrossRef

18.

Buonavoglia A, Leone P, Dammacco R, Di Lernia G, Petruzzi M, Bonamonte D, Vacca A, Racanelli V, Dammacco F (2019) Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy. Autoimmun Rev 18:349–358PubMedCrossRef

19.

Callen JP (2000) Dermatomyositis. Lancet 355:53–57PubMedCrossRef

20.

Callen JP, Wortmann RL (2006) Dermatomyositis. Clin Dermatol 24:363–373PubMedCrossRef

21.

Camisa C, Helm TN (1993) Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol 129:883–886PubMedCrossRef

22.

Carey B, Setterfield J (2019) Mucous membrane pemphigoid and oral blistering diseases. Clin Exp Dermatol 44:732–739PubMedCrossRef

23.

Chen Y‑J, Wu C‑Y, Huang Y‑L, Wang C‑B, Shen J‑L, Chang Y‑T (2010) Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 12:R70PubMedPubMedCentralCrossRef

24.

Cherin P, Herson S, Wechsler B, Bletry O, Degennes C, Piette JC, Ziza JM, Godeau P (1990) Intravenous immunoglobulin for polymyositis and dermatomyositis. Lancet 336:116PubMedCrossRef

25.

Czernik A, Camilleri M, Pittelkow MR, Grando SA (2011) Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol 50:905–914PubMedCrossRef

26.

Di Zenzo G, Thoma-Uszynski S, Fontao L, Calabresi V, Hofmann SC, Hellmark T, Sebbag N, Pedicelli C, Sera F, Lacour J‑P, Wieslander J, Bruckner-Tuderman L, Borradori L, Zambruno G, Hertl M (2008) Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol 128:415–426PubMedCrossRef

27.

Didona D, Di Zenzo G, Joly P (2020a) Paraneoplastic autoimmune multiorgan syndrome (PAMS). G Ital Dermatol Venereol. https://doi.org/10.23736/S0392-0488.20.06675-4

28.

Didona D, Fania L, Didona B, Eming R, Hertl M, Di Zenzo G (2020b) Paraneoplastic dermatoses: a brief general review and an extensive analysis of paraneoplastic pemphigus and paraneoplastic dermatomyositis. Int J Mol Sci 21:. https://doi.org/10.3390/ijms21062178

29.

Didona D, Juratli HA, Scarsella L, Eming R, Hertl M (2020c) The polymorphous spectrum of dermatomyositis: classic features, newly described skin lesions, and rare variants. Eur J Dermatol 30:229–242PubMedCrossRef

30.

Didona D, Juratli HA, Scarsella L, Keber U, Eming R, Hertl M (2020d) Amyopathic and anti-TIF1 gamma-positive dermatomyositis: analysis of a monocentric cohort and proposal to update diagnostic criteria. Eur J Dermatol 30:279–288PubMedCrossRef

31.

Didona D, Maglie R, Eming R, Hertl M (2019) Pemphigus: current and future therapeutic strategies. Front Immunol 10:1418PubMedPubMedCentralCrossRef

32.

Feldman BM, Rider LG, Reed AM, Pachman LM (2008) Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 371:2201–2212PubMedCrossRef

33.

Fried R, Lynfield Y, Vitale P, Anhalt G (1993) Paraneoplastic pemphigus appearing as bullous pemphigoid-like eruption after palliative radiation therapy. J Am Acad Dermatol 29:815–817PubMedCrossRef

34.

Göbel M, Eming R (2019) Therapie des bullösen Pemphigoids. Hautarzt 70:236–242PubMedCrossRef

35.

Göttfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc-Platzer B (2000) High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 10:29–35PubMed

36.

Gualtieri B, Hertl M (2020) Tumorerkrankungen an der Haut erkennen – paraneoplastische Hauterkrankungen. Internist 61:860–868CrossRef

37.

Hammers CM, Stanley JR (2020) Recent advances in understanding Pemphigus and Bullous Pemphigoid. J Invest Dermatol 140:733–741PubMedCrossRef

38.

Hashimoto T (2015) Production of numerous autoantibodies in paraneoplastic pemphigus. Br J Dermatol 172:849–850PubMedCrossRef

39.

Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ (2001) Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 66:142–144PubMedCrossRef

40.

Higo T, Miyagaki T, Nakamura F, Shinohara A, Asano H, Abe H, Senda N, Yoshizaki A, Fukayama M, Kurokawa M (2015) Paraneoplastic pemphigus occurring after bendamustine and rituximab therapy for relapsed follicular lymphoma. Ann Hematol 94:683–685PubMedCrossRef

41.

Hirano T, Higuchi Y, Yuki H, Hirata S, Nosaka K, Ishii N, Hashimoto T, Mitsuya H, Okuno Y (2015) Rituximab monotherapy and Rituximab-containing chemotherapy were effective for Paraneoplastic Pemphigus accompanying follicular lymphoma, but not for subsequent bronchiolitis obliterans. J Clin Exp Hematop 55:83–88PubMedCrossRef

42.

Hofmann SC, Juratli HA, Eming R (2018) Bullöse Autoimmundermatosen. J Dtsch Dermatol Ges 16:1339–1360PubMed

43.

Hohwy T, Bang K, Steiniche T, Peterslund NA, D’Amore F (2004) Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B‑cell chronic lymphocytic leukaemia. Eur J Haematol 73:206–209PubMedCrossRef

44.

Holtsche MM, Zillikens D, Schmidt E (2018) Schleimhautpemphigoid. Hautarzt 69:67–83PubMedCrossRef

45.

Jelti L, Cordel N, Gillibert A, Lacour J‑P, Uthurriague C, Doutre M‑S, Delaporte E, Duvert-Lehembre S, Quereux G, Dupuy A, Adamski H, Bedane C, Misery L, Abasq TC, Fleuret C, Bernard P, Chaby G, D’incan M, Verneuil L, Litrowski N, Joly P (2019) Incidence and mortality of Pemphigus in France. J Invest Dermatol 139:469–473PubMedCrossRef

46.

Joly P, Richard C, Gilbert D, Courville P, Chosidow O, Roujeau JC, Beylot-Barry M, D’incan M, Martel P, Lauret P, Tron F (2000) Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 43:619–626PubMedCrossRef

47.

Kaibuchi-Ando K, Sugiura K, Muro Y, Takahashi Y, Kojima S, Ishii N, Hashimoto T, Akiyama M (2020) Successful treatment with i.v. immunoglobulin and rituximab for bronchiolitis obliterans associated with paraneoplastic pemphigus. J Dermatol 47:e368–e370PubMedCrossRef

48.

Kim JH, Kim S‑C (2019) Paraneoplastic Pemphigus: Paraneoplastic autoimmune disease of the skin and Mucosa. Front Immunol 10:1259PubMedPubMedCentralCrossRef

49.

Lee MS, Kossard S, Ho KK, Barnetson RS, Ravich RB (1995) Paraneoplastic pemphigus triggered by radiotherapy. Australas J Dermatol 36:206–210PubMedCrossRef

50.

Leger S, Picard D, Ingen-Housz-Oro S et al (2012) Prognostic factors of paraneoplastic pemphigus. Arch Dermatol 148:1165–1172PubMedCrossRef

51.

Li D, Tansley SL (2019) Juvenile dermatomyositis-clinical phenotypes. Curr Rheumatol Rep 21:74PubMedPubMedCentralCrossRef

52.

Liu Q, Bu D‑F, Li D, Zhu X‑J (2008) Genotyping of HLA‑I and HLA-II alleles in Chinese patients with paraneoplastic pemphigus. Br J Dermatol 158:587–591PubMedCrossRef

53.

Liu WC, Ho M, Koh W‑P, Tan AWH, Ng PPL, Chua SH, Tan SH, Tang MBY (2010) An 11-year review of dermatomyositis in Asian patients. Ann Acad Med Singap 39:843–847PubMedCrossRef

54.

Lucariello RJ, Villablanca SE, Mascaró JM, Reichel M (2018) Association between bullous pemphigoid and malignancy: a meta-analysis. Australas J Dermatol 59:253–260PubMedCrossRef

55.

Maglie R, Hertl M (2019) Pharmacological advances in pemphigoid. Curr Opin Pharmacol 46:34–43PubMedCrossRef

56.

Maier L, Udvardi A, Hertl M, Eming R, Schmidt E, Zillikens D, Volc-Platzer B (2017) Paraneoplastic pemphigus with anti-BP180 autoantibodies and Castleman disease. Br J Dermatol 176:824–826PubMedCrossRef

57.

Mainetti C, Terziroli Beretta-Piccoli B, Selmi C (2017) Cutaneous manifestations of dermatomyositis: a comprehensive review. Clin Rev Allergy Immunol 53:337–356PubMedCrossRef

58.

Martel P (2003) Paraneoplastic pemphigus is associated with the DRB1*03 allele. J Autoimmun 20:91–95PubMedCrossRef

59.

Mimouni D, Anhalt GJ, Lazarova Z, Aho S, Kazerounian S, Kouba DJ, Mascaro JM, Nousari HC (2002) Paraneoplastic pemphigus in children and adolescents. Br J Dermatol 147:725–732PubMedCrossRef

60.

Moro F, Fania L, Sinagra JLM, Salemme A, Di Zenzo G (2020) Bullous Pemphigoid: trigger and predisposing factors. Biomolecules 10. https://doi.org/10.3390/biom10101432

61.

Motomura K, Yamashita H, Yamada S, Takahashi Y, Kaneko H (2019) Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study. Rheumatol Int 39:1733–1739PubMedCrossRef

62.

Müller R, Heber B, Hashimoto T, Messer G, Müllegger R, Niedermeier A, Hertl M (2009) Autoantibodies against desmocollins in European patients with pemphigus. Clin Exp Dermatol 34:898–903PubMedCrossRef

63.

Nguyen VT, Ndoye A, Bassler KD, Shultz LD, Shields MC, Ruben BS, Webber RJ, Pittelkow MR, Lynch PJ, Grando SA (2001) Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol 137:193–206PubMed

64.

Numata S, Teye K, Tsuruta D, Sogame R, Ishii N, Koga H, Natsuaki Y, Tsuchisaka A, Hamada T, Karashima T, Nakama T, Furumura M, Ohata C, Kawakami T, Schepens I, Borradori L, Hashimoto T (2013) Anti-α-2-macroglobulin-like‑1 autoantibodies are detected frequently and may be pathogenic in paraneoplastic pemphigus. J Invest Dermatol 133:1785–1793PubMedCrossRef

65.

Ohzono A, Sogame R, Li X, Teye K, Tsuchisaka A, Numata S, Koga H, Kawakami T, Tsuruta D, Ishii N, Hashimoto T (2015) Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol 173:1447–1452PubMedCrossRef

66.

Ong E, Goldacre R, Hoang U, Sinclair R, Goldacre M (2014) Associations between bullous pemphigoid and primary malignant cancers: an English national record linkage study, 1999–2011. Arch Dermatol Res 306:75–80PubMedCrossRef

67.

Paolino G, Didona D, Magliulo G, Iannella G, Didona B, Mercuri SR, Moliterni E, Donati M, Ciofalo A, Granata G, Ranuzzi P, Falasca V, Calvieri S (2017) Paraneoplastic Pemphigus: insight into the autoimmune pathogenesis, clinical features and therapy. Int J Mol Sci 18. https://doi.org/10.3390/ijms18122532

68.

Poot AM, Diercks GFH, Kramer D, Schepens I, Klunder G, Hashimoto T, Borradori L, Jonkman MF, Pas HH (2013) Laboratory diagnosis of paraneoplastic pemphigus. Br J Dermatol 169:1016–1024PubMedCrossRef

69.

Porro AM, de Vasconcelos Nasser Caetano L, de Sena Nogueira Maehara L, dos Santos Enokihara MM (2014) Non-classical forms of pemphigus: pemphigus herpetiformis, IgA pemphigus, paraneoplastic pemphigus and IgG/IgA pemphigus. An Bras Dermatol 89:96–106PubMedPubMedCentralCrossRef

70.

Probst C, Schlumberger W, Stöcker W, Recke A, Schmidt E, Hashimoto T, Zhu XJ, Zillikens D, Komorowski L (2009) Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta 410:13–18PubMedCrossRef

71.

Qiang JK, Kim WB, Baibergenova A, Alhusayen R (2017) Risk of malignancy in dermatomyositis and polymyositis. J Cutan Med Surg 21:131–136PubMedCrossRef

72.

Requena C, Alfaro A, Traves V, Nagore E, Llombart B, Serra C, Martorell A, Guillén C, Sanmartín O (2014) Paraneoplastic dermatomyositis: a study of 12 cases. Actas Dermosifiliogr 105:675–682PubMedCrossRef

73.

Sanz-Bueno J, Cullen D, Zarco C, Vanaclocha F (2014) Paraneoplastic autoimmune multiorgan syndrome (paraneoplastic pemphigus) with unusual manifestations and without detectable autoantibodies. Indian J Dermatol Venereol Leprol 80:328–330PubMedCrossRef

74.

Schepens I, Jaunin F, Begre N, Läderach U, Marcus K, Hashimoto T, Favre B, Borradori L (2010) The protease inhibitor alpha-2-macroglobulin-like‑1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. Plos One 5:e12250PubMedPubMedCentralCrossRef

75.

Schmidt E, Meyer-Ter-Vehn T, Zillikens D, Geerling G (2008) Schleimhautpemphigoid mit okulärer beteiligung. Teil I: Klinik, pathogenese und diagnostik. Ophthalmologe 105:285–297 (quiz 298)PubMedCrossRef

76.

Schmidt E, Sticherling M, Sárdy M, Eming R, Goebeler M, Hertl M, Hofmann SC, Hunzelmann N, Kern JS, Kramer H, Nast A, Orzechowski H‑D, Pfeiffer C, Schuster V, Sitaru C, Zidane M, Zillikens D, Worm M (2020) S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update. J Dtsch Dermatol Ges 18:516–526PubMed

77.

Schmidt E, Zillikens D (2010) Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 10:84–89PubMedCrossRef

78.

Schmidt E, Zillikens D (2013) Pemphigoid diseases. Lancet 381:320–332PubMedCrossRef

79.

Solimani F, Maglie R, Pollmann R, Schmidt T, Schmidt A, Ishii N, Tackenberg B, Kirschbaum A, Didona D, Pickert J, Eming R, Hashimoto T, Hertl M (2019a) Thymoma-associated paraneoplastic autoimmune multiorgan syndrome-from pemphigus to lichenoid dermatitis. Front Immunol 10:1413PubMedPubMedCentralCrossRef

80.

Solimani F, Pollmann R, Ishii N, Eming R, Hashimoto T, Schmidt T, Hertl M (2019b) Diagnosis of anti-laminin γ‑1 pemphigoid by immunoblot analysis. J Eur Acad Dermatol Venereol 33:735–741PubMedCrossRef

81.

Stockton D, Doherty VR, Brewster DH (2001) Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 85:41–45PubMedPubMedCentralCrossRef

82.

Taurone S, Spoletini M, Ralli M, Gobbi P, Artico M, Imre L, Czakò C, Kovàcs I, Greco A, Micera A (2019) Ocular mucous membrane pemphigoid: a review. Immunol Res 67:280–289PubMedCrossRef

83.

Volc-Platzer B (2015) Dermatomyositis - update. Hautarzt 66:604–610PubMedCrossRef

84.

Wang J, Zhu X, Li R, Tu P, Wang R, Zhang L, Li T, Chen X, Wang A, Yang S, Wu Y, Yang H, Ji S (2005) Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol 141:1285–1293PubMedCrossRef

85.

Yang Z, Lin F, Qin B, Liang Y, Zhong R (2015) Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 42:282–291PubMedCrossRef

86.

Yildiz O, Ozguroglu M, Yanmaz MT, Turna H, Kursunoglu SG, Antonov M, Serdaroglu S, Demirkesen C, Buyukunal E (2007) Paraneoplastic pemphigus associated with fludarabine use. Med Oncol 24:115–118PubMedCrossRef

87.

Zimmermann J, Bahmer F, Rose C, Zillikens D, Schmidt E (2010) Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges 8:598–606PubMed

Titel: Paraneoplastische Autoimmundermatosen
verfasst von: D. Didona
M. Hertl
Publikationsdatum: 01.03.2021
Verlag: Springer Medizin
Schlagwörter: Dermatomyositis
Bullöses Pemphigoid
Schleimhautpemphigoid
Kutane Paraneoplasien
Kutane Paraneoplasien
Erschienen in: Die Dermatologie / Ausgabe 4/2021
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI: https://doi.org/10.1007/s00105-021-04773-w

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Tumorassoziierte Genodermatosen

One Minute Wonder

Kohortenstudie zur Langzeitbeobachtung von Patienten, bei denen der sog. „molekulare Klassifikator“ zur Unterscheidung von Ekzem und Psoriasis eingesetzt wurde

Neuroendokrine paraneoplastische Syndrome

Fieberschübe >40 °C und urtikarielles Exanthem

Penicillin-Toleranzinduktion in der Schwangerschaft